Anthera Pharma (ANTH) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Anthera Pharma (ANTH) Tops Q1 EPS by 3c

Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update

May 11, 2015 5:30 PM EDT

Completed Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA Nephropathy Increased Cash Position by $43 Million Through Equity Investment by Zenyaku and Equity Offering Received $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Phase 3 Development of Sollpura (liprotamase)

HAYWARD, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced financial results and an operational update for the first quarter ended March 31, 2015.

Net loss for the quarter ended March 31, 2015 was $7.7 million, compared to... More